[{"orgOrder":0,"company":"Innate Pharma","sponsor":"Araris Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Araris Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Araris Biotech"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"IPH5201","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"IPH6401","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"IFLI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ IFLI","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ IFLI"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IPH5201","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IPH45","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IPH4502","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IPH5201","moa":"||CD39","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKCE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKCE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IPH6401","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IPH4502","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"GSK3903371","moa":"IL-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efimosfermin Alpha","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boston Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efimosfermin Alpha","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Boston Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Boston Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, being evaluated for cutaneous T-cell lymphoma and peripheral T cell lymphoma.

                          Product Name : IPH4102

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 17, 2025

                          Lead Product(s) : Lacutamab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 to treat neoplasms.

                          Product Name : IPH4502

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : IPH4502

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : BOS-580 (efimosfermin alfa), is a once-monthly, subcutaneous injection of a long-acting variant of human FGF21 that regulates metabolic pathways in patients with MASH.

                          Product Name : BOS-580

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          November 15, 2024

                          Lead Product(s) : Efimosfermin Alpha

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Araris biotech expands its ip portfolio with the acquisition of innate pharma’s portfolio of transglutaminase patents for the generation of antibody-drug conjugates.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 24, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Araris Biotech

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 to treat neoplasms.

                          Product Name : IPH4502

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          September 23, 2024

                          Lead Product(s) : IPH4502

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : IPH6101 (bexatamig), an investigational CD123 targeting NKp46/CD16-based natural killer cell engager. It is being evaluated for the treatment of R/R acute myeloid leukaemia .

                          Product Name : SAR443579

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 18, 2024

                          Lead Product(s) : Bexatamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : IPH45, a preclinical stage, novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, which is being developed for tumors expressing Nectin-4.

                          Product Name : IPH45

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          June 03, 2024

                          Lead Product(s) : IPH45

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : IPH6501 is a first-in-class antibody targeting CD20, activating NKp46, CD16, and IL-2 receptors, investigated in relapsed/refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma patients.

                          Product Name : IPH6501

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          June 03, 2024

                          Lead Product(s) : IPH6501

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The financing will help Innate to advance its lead product IPH6501, which is being investigated in the early-stage clinical studies for the treatment of patients with relapsed / refractory (R/R) FL.

                          Product Name : IPH6501

                          Product Type : Other Large Molecule

                          Upfront Cash : $3.0 million

                          May 12, 2024

                          Lead Product(s) : IPH6501

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : IFLI

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SAR443579 is an investigational NK cell engager targeting CD123, being evaluated for relapsed/refractory AML, B-cell ALL, and high-risk myelodysplasia.

                          Product Name : SAR443579

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 15, 2024

                          Lead Product(s) : Bexatamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank